Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.8800 UNCHANGED
Last Price Updated: 9:38 AM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kronos Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team 
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope 
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Dr. Besman brings more than 25 years of regulatory affairs and drug development experience and a track record of successfully advancing clinical programs 
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Participation in Upcoming Investor Conferences
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Changes to Board of Directors
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Participation in Upcoming Investor Conferences
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 
From Kronos Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.